share_log

Life Seal Vascular Inc. Awarded Prestigious NSF SBIR Grant to Advance Innovative Endovascular Aortic Aneurysm Sac Management Technology

Life Seal Vascular Inc. Awarded Prestigious NSF SBIR Grant to Advance Innovative Endovascular Aortic Aneurysm Sac Management Technology

Life Seal Vascular公司获得重要的NSF SBIR拨款,推进创新的内血管主动脉动脉瘤囊管理科技。
PR Newswire ·  07/15 11:03

More than $274,000 in NSF funding to develop breakthrough aneurysm sac management technology

美国国家科学基金会拨款超过27.4万美元,用于开发突破性的动脉瘤囊管理技术

COSTA MESA, Calif., July 15, 2024 /PRNewswire/ -- Life Seal Vascular Inc. (), a pioneering company dedicated to revolutionizing endovascular treatment, is thrilled to announce that it has been awarded the highly competitive National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant. This funding will accelerate the development of Life Seal Vascular's cutting-edge technology to improve patient outcomes and advance the field of endovascular aortic repair (EVAR).

加利福尼亚州科斯塔梅萨,2024年7月15日 /PRNewswire/ — 致力于革新血管内治疗的开创性公司Life Seal Vascular Inc. () 很高兴地宣布,它已获得竞争激烈的国家科学基金会(NSF)小型企业创新研究(SBIR)资助。这笔资金将加速Life Seal Vascular尖端技术的开发,以改善患者预后并推进血管内主动脉修复(EVAR)领域。

Life Seal Concept
生命印章概念

"We are honored to receive this prestigious SBIR grant from the NSF. This funding is a testament to the innovative potential of our technology and our commitment to advancing EVAR care," said Bob Mitchell, Executive Chairman of the Board at Life Seal Vascular Inc. "With this support, we are well-positioned to advance the development of our breakthrough aneurysm sealing solutions and make a significant impact on the lives of EVAR patients worldwide."

“我们很荣幸获得美国国家科学基金会的这笔久负盛名的SBIR资助。这笔资金证明了我们技术的创新潜力以及我们对推进EVAR护理的承诺,” Life Seal Vascular Inc董事会执行主席鲍勃·米切尔说,“有了这种支持,我们完全有能力推进突破性动脉瘤密封解决方案的开发,并对全球EVAR患者的生活产生重大影响。”

The NSF SBIR grant will enable Life Seal Vascular to further develop its proprietary aneurysmal sac sealing technology. Designed as an adjunctive therapy to native endografts, Life Seal Vascular's groundbreaking approach seals the entire aneurysmal sac potentially eliminating endoleaks, reducing reintervention rates and improving clinical outcomes for EVAR patients.

NSF SBIR拨款将使Life Seal Vascular能够进一步开发其专有的动脉瘤囊密封技术。Life Seal Vascular的开创性方法是天然内移植的辅助疗法,其开创性的方法可以密封整个动脉瘤囊,有可能消除内渗漏,降低再干预率,改善EVAR患者的临床结果。

Dr. Michel Reijnen, a renowned vascular surgeon, commented on the significance of Life Seal Vascular's technology, stating, "The advancements being made by Life Seal Vascular are truly remarkable. Their innovative solutions have the potential to revolutionize EVAR, offering patients safer and more effective treatment options. I am excited to see the positive impact this technology will have on the field and on patient care."

著名血管外科医生米歇尔·雷杰宁博士评论了Life Seal Vascular的技术的重要性,他说:“Life Seal Vascular取得的进步确实非常了不起。他们的创新解决方案有可能彻底改变EVAR,为患者提供更安全、更有效的治疗选择。我很高兴看到这项技术将对现场和患者护理产生积极影响。”

The NSF SBIR program is a highly competitive initiative that supports scientific excellence and technological innovation through the investment of federal research funds. Life Seal Vascular's selection for this grant underscores the company's dedication to advancing medical technology and its potential to deliver transformative healthcare solutions.

NSF SBIR计划是一项竞争激烈的计划,通过联邦研究资金的投资来支持卓越的科学和技术创新。Life Seal Vascular选择这笔拨款凸显了该公司致力于推进医疗技术的发展及其提供变革性医疗解决方案的潜力。

This grant is supported by the U.S. National Science Foundation under award number 2407378.

该补助金由美国国家科学基金会支持,奖励编号为2407378。

About Life Seal Vascular, Inc.
Life Seal Vascular Inc. specializes in innovative sealing technologies for endovascular repair of aortic aneurysms. Their proprietary solutions has the potential to eliminate endoleaks, the main cause of reinterventions in Endovascular Aneurysm Repair (EVAR). By completely sealing the aneurysm, Life Seal Vascular's devices ensure predictable deployment and do not interfere with imaging, thereby enhancing the effectiveness and safety of endovascular repair procedures.

关于 Life Seal Vascular, Inc
Life Seal Vascular Inc. 专门研究用于主动脉瘤血管内修复的创新密封技术。他们的专有解决方案有可能消除内渗漏,这是血管内动脉瘤修复(EVAR)再干预的主要原因。通过完全密封动脉瘤,Life Seal Vascular的设备可确保可预测的部署且不会干扰成像,从而提高血管内修复手术的有效性和安全性。

For more information about Life Seal Vascular Inc. and its groundbreaking technology, please visit []().

有关 Life Seal Vascular Inc. 及其开创性技术的更多信息,请访问 [] ()。

About U.S. National Science Foundation Small Business Program
America's Seed Fund powered by the U.S. National Science Foundation Small Business programs focuses on transforming scientific and engineering discoveries into products and services with commercial and societal impact. The deep technologies that are funded show promise, but their success hasn't yet been validated. And, each year, the NSF awards $200+ million in research and development (R&D) funding to about 400 startups across the United States. America's Seed Fund is a program within the National Science Foundation and housed within the Directorate for Technology, Innovation and Partnerships.

关于美国国家科学基金会小企业计划
美国种子基金由美国国家科学基金会小型企业项目提供支持,专注于将科学和工程发现转化为具有商业和社会影响的产品和服务。获得资助的深度技术显示出希望,但其成功尚未得到证实。而且,NSF每年向美国约400家初创公司提供超过2亿美元的研发(R&D)资金。美国种子基金是美国国家科学基金会下属的一项计划,设在技术、创新和伙伴关系局内。

Media Contact:
Bob Mitchell
Executive Chairman of the Board

媒体联系人:
鲍勃米切尔
董事会执行主席

Life Seal Vascular Inc.
Hannah Friend
602-618-3377
[email protected]

Life Seal 血管公司
汉娜·弗里德
602-618-3377
[电子邮件保护]

SOURCE Life Seal Vascular, Inc.

来源 Life Seal Vascular, Inc

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发